Participant flow

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST · Source last updated 2022-10-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   300 mg PO QD avapritinib: Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.

   id

   FG000

   title

   Avapritinib

2. description

   160 mg PO QD regorafenib: Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).

   id

   FG001

   title

   Regorafinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         21

      2. group Id

         FG001

         num Subjects

         14

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         89

      2. group Id

         FG001

         num Subjects

         87

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         3

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         33

      2. group Id

         FG001

         num Subjects

         32

      type

      Administrative/Other

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         2

      type

      Not treated

   6. reasons

      1. group Id

         FG000

         num Subjects

         91

      2. group Id

         FG001

         num Subjects

         98

      type

      Sponsor decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         240

      2. group Id

         FG001

         num Subjects

         236

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         240

      2. group Id

         FG001

         num Subjects

         236

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice